PT  - JOURNAL ARTICLE
AU  - Alswat, Khalid A.
AU  - Fallatah, Hind I.
AU  - Al-Judaibi, Bandar
AU  - Elsiesy, Hussien A,
AU  - Al-Hamoudi, Waleed K.
AU  - Qutub, Adel N.
AU  - Alturaify, Naif
AU  - Al-Osaimi, Abdullah
TI  - Position statement on the diagnosis and management of non-alcoholic fatty liver disease
AID  - 10.15537/smj.2019.6.23980
DP  - 2019 Jun 01
TA  - Saudi Medical Journal
PG  - 531--540
VI  - 40
IP  - 6
4099  - http://smj.org.sa/content/40/6/531.short
4100  - http://smj.org.sa/content/40/6/531.full
SO  - Saudi Med J2019 Jun 01; 40
AB  - Non-alcoholic fatty liver disease (NAFLD) is a major national and international health burden. It is one of the most common liver diseases worldwide and the most common cause of abnormal liver enzymes in many developed countries. Non-alcoholic fatty liver disease is also known as an important cause of cryptogenic cirrhosis and second leading cause for liver transplantation. It is commonly associated with metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is the progressive phenotype of NAFLD. In spite of promising performance of non-invasive tools, liver biopsy remains the gold standard test for NASH diagnosis. Over decades, many drugs have been investigated in phase 2 and 3; however, no approved therapy to date. Despite the alarming global rates of NAFLD, there are no local community-based studies on the prevalence of NAFLD or local practice guidelines on its management; this expert review aims to fill this gap.